The Revolution of Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy
worldwide and causes significant morbidity and mortality. For decades, medical treatment …
worldwide and causes significant morbidity and mortality. For decades, medical treatment …
Current perspectives of sudden cardiac death management in hypertrophic cardiomyopathy
L Pu, J Li, W Qi, J Zhang, H Chen, Z Tang, Y Han… - Heart Failure …, 2024 - Springer
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder characterized by
left ventricular hypertrophy. Sudden cardiac death (SCD) is a rare but the most catastrophic …
left ventricular hypertrophy. Sudden cardiac death (SCD) is a rare but the most catastrophic …
Comparative Influences of Beta blockers and Verapamil on Cardiac Outcomes in Hypertrophic Cardiomyopathy
Guidelines recommend β blockers (BBs) as first-line therapy in symptomatic patients with
hypertrophic cardiomyopathy (HCM) and nondihydropyridine calcium channel blockers …
hypertrophic cardiomyopathy (HCM) and nondihydropyridine calcium channel blockers …
The Role of Angiotensin II Receptor Blockers in the Management of Hypertrophic Cardiomyopathy: An Updated Meta-Analysis of Randomized Controlled Trials
Y Wan, S He, T Xu, S Wang, M Qi, P Gan - Cardiology, 2024 - karger.com
Introduction: The use of angiotensin II receptor blockers (ARBs) in the treatment of
hypertrophic cardiomyopathy (HCM) remains a subject of controversy. Methods: We …
hypertrophic cardiomyopathy (HCM) remains a subject of controversy. Methods: We …
How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions
K Del Vecchio, C Rizzardi, A Pozza… - … Archives for Chest …, 2024 - monaldi-archives.org
Pediatric hypertrophic cardiomyopathy (HCM) has a wide range of clinical manifestations.
Left ventricular outflow tract obstruction (LVOTO) at rest is present in up to one-third of …
Left ventricular outflow tract obstruction (LVOTO) at rest is present in up to one-third of …
Calling the Right Plays in Hypertrophic Cardiomyopathy: Are Our Blockers Optimized for the Game?
S Abou Alaiwi, LE Rosenfeld - American Journal of Cardiology, 2024 - ajconline.org
The history of using non-vasodilating beta blockers (BB) s and non-dihydropyridine calcium
channel blockers (ND-CCB) s to treat hypertrophic cardiomyopathy (HCM) spans over half a …
channel blockers (ND-CCB) s to treat hypertrophic cardiomyopathy (HCM) spans over half a …
Resolution of dynamic left ventricular outflow tract obstruction and reversible left ventricular hypertrophy in 4 cats
K Buchanan, C Lynn, C Hallman… - The Canadian …, 2024 - ingentaconnect.com
This case series describes spontaneous resolution of systolic anterior motion of the mitral
valve, cessation of a dynamic left ventricular outflow tract obstruction, and reverse cardiac …
valve, cessation of a dynamic left ventricular outflow tract obstruction, and reverse cardiac …
[HTML][HTML] Anesthetic Precision in Severe Hypertrophic Cardiomyopathy: Navigating Perioperative Challenges
P Hannurkar, U Phad, C Suryawanshi - Cureus, 2024 - pmc.ncbi.nlm.nih.gov
Managing a patient with hypertrophic obstructive cardiomyopathy (HOCM) presents a
significant challenge for any anesthesiologist. A deep understanding of the pathophysiology …
significant challenge for any anesthesiologist. A deep understanding of the pathophysiology …
Hipertrofine Kardiomiopatija Sergančiųjų Pacientų Klinikinių, Laboratorinių, Krūvio Echokardiografijos Rodiklių Sąsajos ir Įtaka Gydymo Taktikos Pasirinkimui
I Petkutė - 2024 - search.proquest.com
Tyrimo tikslas. Įvertinti klinikinius, laboratorinius rodiklius, genetinius tyrimus,
echokardiografijos duomenis–sergantiems hipetrofine kardiomiopatija (HKMP), kuriems …
echokardiografijos duomenis–sergantiems hipetrofine kardiomiopatija (HKMP), kuriems …